drugset / Trial / NCT04796831
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
NaSingle-groupOpen-labelTreatment
Summary
Quizartinib, a selective FLT3 inhibitor, is being developed as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The absolute oral bioavailability of quizartinib has not yet been studied. This study is designed to estimate quizartinib bioavailability of quizartinib following oral and intravenous (IV) administration.
Timeline
- Start
- 2021-04-26
- Primary completion
- 2021-06-11
- Completion
- 2021-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quizartinib | Small molecule | 50 ug | Oral |
| Subject | Quizartinib | Small molecule | 60 mg | Oral |
Indications
No indication recorded.